Global Age-Related Macular Degeneration (AMD) Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029
Page: 85
Published Date: 11 Jan 2023
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
Age-related macular degeneration is a bilateral ocular condition in which the central area of the retina, known as the macula, is affected.
According to our (Global Info Research) latest study, the global Age-Related Macular Degeneration (AMD) Therapeutics market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Age-related macular degeneration is a progressive condition, and it is common among the geriatric population. The growing geriatric population is contributing to the rising incidence of age-related macular degeneration globally. As a result, there is a high demand for therapeutics to treat the condition. Pharmaceutical companies are leveraging this opportunity and are focusing on releasing drugs to treat age-related macular degeneration.
This report is a detailed and comprehensive analysis for global Age-Related Macular Degeneration (AMD) Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Age-Related Macular Degeneration (AMD) Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
Global Age-Related Macular Degeneration (AMD) Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Age-Related Macular Degeneration (AMD) Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Age-Related Macular Degeneration (AMD) Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Age-Related Macular Degeneration (AMD) Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Age-Related Macular Degeneration (AMD) Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen Inc., Bausch Health Companies, Inc., F. Hoffmann-La Roche Ltd., Novartis AG and Regeneron Pharmaceuticals Inc.. etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Age-Related Macular Degeneration (AMD) Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Wet AMD
Dry AMD
Market segment by Application
Hospital
Clinic
Research Institute
Other
Market segment by players, this report covers
Amgen Inc.
Bausch Health Companies, Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Age-Related Macular Degeneration (AMD) Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Age-Related Macular Degeneration (AMD) Therapeutics, with revenue, gross margin and global market share of Age-Related Macular Degeneration (AMD) Therapeutics from 2018 to 2023.
Chapter 3, the Age-Related Macular Degeneration (AMD) Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Age-Related Macular Degeneration (AMD) Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Age-Related Macular Degeneration (AMD) Therapeutics.
Chapter 13, to describe Age-Related Macular Degeneration (AMD) Therapeutics research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Age-Related Macular Degeneration (AMD) Therapeutics
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Age-Related Macular Degeneration (AMD) Therapeutics by Type
1.3.1 Overview: Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Type in 2022
1.3.3 Wet AMD
1.3.4 Dry AMD
1.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Market by Application
1.4.1 Overview: Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Research Institute
1.4.5 Other
1.5 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size & Forecast
1.6 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast by Region
1.6.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region, (2018-2029)
1.6.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Prospect (2018-2029)
1.6.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Prospect (2018-2029)
1.6.6 South America Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Prospect (2018-2029)
2.1 Amgen Inc.
2.1.1 Amgen Inc. Details
2.1.2 Amgen Inc. Major Business
2.1.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
2.1.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Amgen Inc. Recent Developments and Future Plans
2.2 Bausch Health Companies, Inc.
2.2.1 Bausch Health Companies, Inc. Details
2.2.2 Bausch Health Companies, Inc. Major Business
2.2.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
2.2.4 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Bausch Health Companies, Inc. Recent Developments and Future Plans
2.3 F. Hoffmann-La Roche Ltd.
2.3.1 F. Hoffmann-La Roche Ltd. Details
2.3.2 F. Hoffmann-La Roche Ltd. Major Business
2.3.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
2.3.4 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
2.4.4 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Novartis AG Recent Developments and Future Plans
2.5 Regeneron Pharmaceuticals Inc.
2.5.1 Regeneron Pharmaceuticals Inc. Details
2.5.2 Regeneron Pharmaceuticals Inc. Major Business
2.5.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
2.5.4 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Regeneron Pharmaceuticals Inc. Recent Developments and Future Plans
3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Age-Related Macular Degeneration (AMD) Therapeutics by Company Revenue
3.2.2 Top 3 Age-Related Macular Degeneration (AMD) Therapeutics Players Market Share in 2022
3.2.3 Top 6 Age-Related Macular Degeneration (AMD) Therapeutics Players Market Share in 2022
3.3 Age-Related Macular Degeneration (AMD) Therapeutics Market: Overall Company Footprint Analysis
3.3.1 Age-Related Macular Degeneration (AMD) Therapeutics Market: Region Footprint
3.3.2 Age-Related Macular Degeneration (AMD) Therapeutics Market: Company Product Type Footprint
3.3.3 Age-Related Macular Degeneration (AMD) Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value and Market Share by Type (2018-2023)
4.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast by Type (2024-2029)
5.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Application (2018-2023)
5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast by Application (2024-2029)
6.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2018-2029)
6.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2018-2029)
6.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
6.3.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Country (2018-2029)
6.3.2 United States Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
6.3.3 Canada Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
6.3.4 Mexico Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
7.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2018-2029)
7.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2018-2029)
7.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
7.3.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Country (2018-2029)
7.3.2 Germany Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
7.3.3 France Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
7.3.5 Russia Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
7.3.6 Italy Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
8.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region
8.3.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Region (2018-2029)
8.3.2 China Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
8.3.3 Japan Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
8.3.4 South Korea Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
8.3.5 India Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
8.3.7 Australia Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
9.1 South America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2018-2029)
9.2 South America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2018-2029)
9.3 South America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
9.3.1 South America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Country (2018-2029)
9.3.2 Brazil Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
9.3.3 Argentina Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
10.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
10.3.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Country (2018-2029)
10.3.2 Turkey Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
10.3.4 UAE Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2029)
11.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers
11.2 Age-Related Macular Degeneration (AMD) Therapeutics Market Restraints
11.3 Age-Related Macular Degeneration (AMD) Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12.1 Age-Related Macular Degeneration (AMD) Therapeutics Industry Chain
12.2 Age-Related Macular Degeneration (AMD) Therapeutics Upstream Analysis
12.3 Age-Related Macular Degeneration (AMD) Therapeutics Midstream Analysis
12.4 Age-Related Macular Degeneration (AMD) Therapeutics Downstream Analysis
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Amgen Inc. Company Information, Head Office, and Major Competitors
Table 6. Amgen Inc. Major Business
Table 7. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
Table 8. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Amgen Inc. Recent Developments and Future Plans
Table 10. Bausch Health Companies, Inc. Company Information, Head Office, and Major Competitors
Table 11. Bausch Health Companies, Inc. Major Business
Table 12. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
Table 13. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Bausch Health Companies, Inc. Recent Developments and Future Plans
Table 15. F. Hoffmann-La Roche Ltd. Company Information, Head Office, and Major Competitors
Table 16. F. Hoffmann-La Roche Ltd. Major Business
Table 17. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
Table 18. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
Table 20. Novartis AG Company Information, Head Office, and Major Competitors
Table 21. Novartis AG Major Business
Table 22. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
Table 23. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Novartis AG Recent Developments and Future Plans
Table 25. Regeneron Pharmaceuticals Inc. Company Information, Head Office, and Major Competitors
Table 26. Regeneron Pharmaceuticals Inc. Major Business
Table 27. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
Table 28. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Regeneron Pharmaceuticals Inc. Recent Developments and Future Plans
Table 30. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million) by Players (2018-2023)
Table 31. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Players (2018-2023)
Table 32. Breakdown of Age-Related Macular Degeneration (AMD) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 33. Market Position of Players in Age-Related Macular Degeneration (AMD) Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 34. Head Office of Key Age-Related Macular Degeneration (AMD) Therapeutics Players
Table 35. Age-Related Macular Degeneration (AMD) Therapeutics Market: Company Product Type Footprint
Table 36. Age-Related Macular Degeneration (AMD) Therapeutics Market: Company Product Application Footprint
Table 37. Age-Related Macular Degeneration (AMD) Therapeutics New Market Entrants and Barriers to Market Entry
Table 38. Age-Related Macular Degeneration (AMD) Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 39. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (USD Million) by Type (2018-2023)
Table 40. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Share by Type (2018-2023)
Table 41. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Forecast by Type (2024-2029)
Table 42. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2018-2023)
Table 43. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Forecast by Application (2024-2029)
Table 44. North America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 45. North America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 46. North America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 47. North America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 48. North America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 49. North America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 50. Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 51. Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 52. Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 53. Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 54. Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 55. Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 56. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 57. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 58. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 59. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 60. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 61. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 62. South America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 63. South America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 64. South America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 65. South America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 66. South America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 67. South America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 68. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 69. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 70. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 71. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 72. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 73. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 74. Age-Related Macular Degeneration (AMD) Therapeutics Raw Material
Table 75. Key Suppliers of Age-Related Macular Degeneration (AMD) Therapeutics Raw Materials
List of Figures
Figure 1. Age-Related Macular Degeneration (AMD) Therapeutics Picture
Figure 2. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Type in 2022
Figure 4. Wet AMD
Figure 5. Dry AMD
Figure 6. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Application in 2022
Figure 8. Hospital Picture
Figure 9. Clinic Picture
Figure 10. Research Institute Picture
Figure 11. Other Picture
Figure 12. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Market Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 15. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 16. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Region in 2022
Figure 17. North America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. South America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 22. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Players in 2022
Figure 23. Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 24. Global Top 3 Players Age-Related Macular Degeneration (AMD) Therapeutics Market Share in 2022
Figure 25. Global Top 6 Players Age-Related Macular Degeneration (AMD) Therapeutics Market Share in 2022
Figure 26. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Share by Type (2018-2023)
Figure 27. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share Forecast by Type (2024-2029)
Figure 28. Global Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Share by Application (2018-2023)
Figure 29. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share Forecast by Application (2024-2029)
Figure 30. North America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 31. North America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 32. North America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 33. United States Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 34. Canada Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 35. Mexico Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 36. Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 37. Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 38. Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 39. Germany Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 40. France Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 41. United Kingdom Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 42. Russia Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 43. Italy Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 44. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 45. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 46. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 47. China Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 48. Japan Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 49. South Korea Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 50. India Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 51. Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 52. Australia Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 53. South America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 54. South America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 55. South America Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 56. Brazil Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 57. Argentina Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 58. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 59. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 60. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 61. Turkey Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 62. Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 63. UAE Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 64. Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers
Figure 65. Age-Related Macular Degeneration (AMD) Therapeutics Market Restraints
Figure 66. Age-Related Macular Degeneration (AMD) Therapeutics Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Manufacturing Cost Structure Analysis of Age-Related Macular Degeneration (AMD) Therapeutics in 2022
Figure 69. Manufacturing Process Analysis of Age-Related Macular Degeneration (AMD) Therapeutics
Figure 70. Age-Related Macular Degeneration (AMD) Therapeutics Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Amgen Inc. Bausch Health Companies, Inc. F. Hoffmann-La Roche Ltd. Novartis AG Regeneron Pharmaceuticals Inc.
Related Reports
19 Jan 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
